Metered transdermal estradiol spray may cause ipsilateral hyperpigmentation of the nipple and areola.
Cases:
Two women who were using transdermal estradiol spray for the treatment of postmenopausal symptoms developed hyperpigmentation of the ipsilateral areola and nipple. The appearance was variable in onset and did not appear to be related to the duration of use.
Conclusion:
Estradiol transdermal spray can have the rare side effect of ipsilateral nipple and areolar hyperpigmentation. The time of onset can vary.
Get full access to this article
View all access options for this article.
References
1.
BusterJE, KoltonWD, PascualML, DayWW, PetersonC. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol, 2008; 11:1343–1351.
2.
JangYH, LeeJY, KangHY, LeeES, KimYC. Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis. J Eur Acad Dermatol Venereol, 2010; 24:1312–1316.
3.
BeasF, VargasL, SpadaRP, MerchakN. Pseudoprecocious puberty in infants caused by a dermal ointment containing estrogens. J Pediatr, 1969; 75:127–130.
4.
WintonGB, LewisCW. Dermatoses of pregnancy. J Am Acad Dermatol, 1982; 6:977–998.
5.
DivenDG, CrawfordJM. Ipsilateral areolar hyperpigmentation following unilateral application of estradiol spray. Am J Obstet Gynecol, 2010; 203,5:e8.
6.
SchumacherRJ, GattermeirDJ, PetersonCA, WisdomC, DayWW. The effect of skin to skin contact, application site washing and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray. Menopause, 2009; 16:177–183.
7.
U.S. Food and Drug Administration. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm220217.htm. 2011 December 6.
8.
HolstJ, CarlstromK, von SchoultzB. Serum estrogen levels after topical application of estradiol-17 beta on two different cutaneous areas. Acta Obstet Gynecol Scand, 1987; 66:151–152.
